Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01546883 · ClinicalTrials.gov registry record · Phase 4
Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation
A Phase 4 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT01546883 is a Phase 4 study that was terminated before completion, run by University of Utah. The registered enrollment target is 14 participants.
The verdict
NCT01546883, a Phase 4 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study includes treating patients with atrial fibrillation (AF) with Dabigatran, an anti-coagulant for a period of one year to see if there are any significant changes in the degree of left atrial structural remodeling in these patients. The investigators hypothesize that there will be a significant decrease in the degree of left atrial structural remodeling (fibrosis) in AF patients treated with dabigatran.
Interventions
- DRUG Dabigatran etexilate (Pradaxa)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01546883
The ClinicalTrials.gov registry entry for NCT01546883 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dabigatran etexilate (Pradaxa) is the first listed.
NCT01546883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01546883 about?
NCT01546883 is a clinical study titled "Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation". This study includes treating patients with atrial fibrillation (AF) with Dabigatran, an anti-coagulant for a period of one year to see if there are any significant changes in the degree of left atrial structural remodeling in these patients. The investigators hypothesize that there will be a signifi...
What is the current status of trial NCT01546883?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2012-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01546883?
The interventions under investigation include: Dabigatran etexilate (Pradaxa) (DRUG).
Who is sponsoring clinical trial NCT01546883?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.